Global Life Science Leader [ ]
BGI’s unparalleled understanding of its clients’ competitive landscape in conjunction with best-in-class executive through board level recruiting makes it the search firm of choice with clients that are truly focused on driving their success and bringing exceptional shareholder value.
 CEO Board Executive Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Biotechnology Pharmaceutical Medical Device Contract Services Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Saving Lives Improving Treatments Learn More Maximizing Shareholder Value Finding Cures Helping Clients

Encompassing all Executive through Board Positions in Life Sciences

Director of the Board

Yes

Chief Executive Officer

Yes

Chief Business Officer

Leading publicly traded biopharmaceutical stem cell company.

No

Chairman of the Board

Yes

Chief Financial Officer

Formerly Aastrom Biosciences

Yes

Chief Operating Officer

Yes

Chief Scientific Officer

Leading publicly traded monoclonal antibody & oncology company

No

Executive Vice President, Orthopedics and Chief Operating Officer

Formerly BioMimetic Therapeutics, Inc.

Yes
See More

In The News

The agency identified 76 cases of drug-induced liver injury in patients who used Amgen’s Tavneos, including eight deaths.

https://www.fiercepharma.com/pharma/fda-flags-serious-liver-injury-concerns-fatalities-linked-amgens-tavneos

Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its production facility in Bloomington, Indiana, which chips in on the blockbuster GLP-1 medications Ozempic and Wegovy.

https://www.fiercepharma.com/manufacturing/novo-nordisk-cuts-hundreds-roles-troubled-bloomington-site

Irish antibiotic specialist Iterum Therapeutics has started winding down its operations, citing limited cash amid the expensive commercialization of its only approved product, Orlynvah.

https://www.fiercepharma.com/pharma/iterum-initiates-wind-down-after-failure-offload-antibiotic-sluggish-sales

Biogen is bulking up in immunology—and paving the way for its future ambitions in kidney diseases—with an M&A play that immediately adds two ongoing launches to its marketed drugs portfolio.

https://www.fiercepharma.com/pharma/biogen-ponies-56b-apellis-and-its-pair-approved-meds-eyeing-swift-immunology-tailwind

BASF Pharma Solutions will raise its prices by up to 20% for its excipients and some of its active pharmaceutical ingredients (APIs), effective immediately.

https://www.fiercepharma.com/manufacturing/api-supplier-basf-raises-prices-20-response-rising-energy-costs

Insulet has reinstated the chief commercial officer position three years after eliminating the role to pursue more focused regional and local market execution.

https://www.fiercepharma.com/marketing/insulet-hires-stryker-vet-reinstating-commercial-chief-role-c-suite-overhaul-continues

Piper Sandler Spring Biopharma Symposium
Boston, MA April 15-16

Needham & Co. Annual Healthcare Conference
New York, NY April 13-16

Society of Gynecologic Oncology Annual Meeting (SGO)
San Juan, Puerto Rico April 11-13

American Academy of Dermatology (AAD)
Denver, CO March 27-30

Society of Toxicology Annual Meeting (SOT)
San Diego, CA March 22-26

American Society of Clinical Oncology Genitourinary Cancers Symposium
San Francisco, CA February 26-28

See More Events

Read More Articles